Through the Rapid Response Partnership Vehicle (RRPV), managed by Advanced Technology International (ATI), BARDA is announcing the newest solicitation opportunities for the development of next generation COVID-19 vaccines, therapeutics, and enabling technologies under Project NextGen. 

Project NextGen, which BARDA co-leads with the National Institute of Allergy and Infectious Diseases (NIAID), is advancing vaccines and therapeutics that are more durable and effective across variants as well as enabling technologies that will together improve the fight against COVID-19 and transform the response to future health security threats.  The RRPV – a new multipurpose acquisition vehicle – supports BARDA’s research and development mission and aims to advance health security, enhance preparedness, and enable a rapid response to the next pandemic or public health emergency. Learn more and apply.